

IN THE CLAIMS:

1. (currently amended) A pharmaceutical preparation which comprises an amount, sufficient for promoting coagulation, of natural or synthetic RNA or of one or more coagulation-promoting fragments of natural or synthetic RNA, RNA analogs, ~~such as~~ peptide-nucleic acids, ribozymes or RNA aptamers.

2. (currently amended) ~~[[A]]~~ The pharmaceutical preparation as claimed in claim 1, which, ~~in addition to the amount promoting coagulation, of natural or synthetic RNA or of one or more coagulation-promoting fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers,~~ further comprises an activator for a plasma coagulation factor.

3. (currently amended) ~~[[A]]~~ The pharmaceutical preparation as claimed in claim 2, which comprises factor VII activating protease (~~=FSAP~~) or its proenzyme as activator.

4. (currently amended) A method for promoting coagulation, comprising administering the ~~The use of a pharmaceutical preparation as claimed in any one of claims 1-3 to a patient 1 to 3, which is employed for promoting coagulation.~~

5. (original) A pharmaceutical preparation, which comprises an amount, sufficient for promoting fibrinolysis or inhibiting coagulation, of one or more RNA-degrading or -inhibiting compounds with ribonucleolytic activity or RNA-complexing capacity.

6. (currently amended) ~~[[A]] The pharmaceutical preparation as claimed in claim 5, which, in addition to an amount, sufficient for promoting fibrinolysis or inhibiting coagulation, of one or more RNA-degrading, inhibiting or masking compounds, further~~ comprises an activator for a plasma fibrinolytic.

7. (currently amended) ~~[[A]] The pharmaceutical preparation as claimed in claim 6, which comprises a plasminogen activator~~ factor VII-activating protease FSAP or its proenzyme as activator for a plasma fibrinolytic.

8. (currently amended) A diagnostic aid for detecting ~~inter alia~~ postoperative hypercoagulable states, complications of pregnancy, tumor status, acute myocardial infarction or sepsis, ~~which comprises~~ wherein said diagnostic aid is used in the detection of an increased plasma RNA content compared with healthy people.

9. (currently amended) A diagnostic aid for quantitative or qualitative detection of coagulation factor VII-activating protease ~~FSAP~~ or of its proenzyme, which comprises[[,]] a sufficient amount of natural or synthetic RNA, of active fragments of natural or synthetic RNA or RNA analogs, peptide nucleic acids, ribozymes or RNA aptamers for determination

- a) of the inactivating effect on coagulation factors VIII/VIIIa or V/Va or
- b) of the shortening effect on coagulation times in global coagulation tests or
- c) of the activating effect on plasminogen activators or
- d) of the activating effect on FVII

~~a sufficient amount of natural or synthetic RNA, of active fragments of natural or synthetic RNA or RNA analogs such as peptide nucleic acids, ribozymes or RNA aptamers.~~

10. (currently amended) A diagnostic aid as claimed in claim 8, which comprises[[,]] a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers for determination of the effect shortening the coagulation time by means

- a) of the non-activated partial thromboplastin time (NAPTT) or
- b) of the prothrombin time (PT) or
- c) of the plasma recalcification time or
- d) of the activated partial thromboplastin time (APTT)

~~a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers.~~

11. (currently amended) A diagnostic aid as claimed in claim[[s]] 8 ~~and~~ or 9, which comprises[[,]] a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers for determination of the effect activating or enhancing the plasminogen activators through the activation

a) of single-chain urokinase (scuPA, single-chain urokinase plasminogen activator)

or

b) of single-chain tPA (sctPA, single-chain tissue plasminogen activator)[[,]]

~~a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers.~~

12. (original) A pharmaceutical preparation as claimed in claim 5, which comprises an amount, sufficient for the treatment of sepsis, of one or more RNA-degrading, inhibiting or complexing compounds.